According to Grifols's latest financial reports the company has $0.57 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $0.61 B | -79.59% |
2021-12-31 | $3.03 B | 318.09% |
2020-12-31 | $0.72 B | -73.74% |
2019-12-31 | $2.76 B | 122.3% |
2018-12-31 | $1.24 B | 16.92% |
2017-12-31 | $1.06 B | 12.96% |
2016-12-31 | $0.94 B | -24.58% |
2015-12-31 | $1.24 B | -4.82% |
2014-12-31 | $1.31 B | 34.09% |
2013-12-31 | $0.97 B | 56.34% |
2012-12-31 | $0.62 B | 37.56% |
2011-12-31 | $0.45 B | 35.47% |
2010-12-31 | $0.33 B | -8.96% |
2009-12-31 | $0.36 B | 1926.75% |
2008-12-31 | $18.2 M | -2.34% |
2007-12-31 | $18.64 M | -57.41% |
2006-12-31 | $43.77 M | 57.52% |
2005-12-31 | $27.78 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $22.92 B | 3,891.72% | ๐บ๐ธ USA |
Amgen AMGN | $10.94 B | 1,805.41% | ๐บ๐ธ USA |
Baxter BAX | $3.19 B | 456.09% | ๐บ๐ธ USA |
Kimberly-Clark KMB | $1.09 B | 90.30% | ๐บ๐ธ USA |